icon-    folder.gif   Conference Reports for NATAP  
 
  (APASL) 23rd Conference of the Asian Pacific
Association for the Study of the Liver
6-9 June
2013, Singapore
Back grey_arrow_rt.gif
 
 
 
Vaniprevir (MK-7009) in Treatment-Experienced Genotype (GT) 1 HCV-Infected Patients Demonstrates Time-Dependent Pharmacokinetics (PK)
 
 
  Reported by Jules Levin
APASL- Asian Pacific Association Liver Week
23rd Conference June 6 - 10, 2013, Singapore
 
Gao W, Caro L, Du L, Han L, Anderson M, Hwang P, Bhanja S, Su J, Mobashery N Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
 
AASLD 2011: A Phase 2b Study of MK-7009 (vaniprevir) in Patients with Genotype 1 HCV Infection Who HaveFailed Previous Pegylated Interferon and Ribavirin Treatment........http://www.natap.org/2011/AASLD/AASLD_55.htm
 
AASLD Nov 3 2008: Safety, Tolerability and Antiviral Activity of MK-7009, a Novel
 
AASLD Nov 5-8 2011: Safety and Efficacy of Vaniprevir (MK-7009) in Combination with Peg-interferon a-2a (Peg-IFN)/Ribavirin (RBV) in Genotype 1 Treatment-Experienced HCV-Infected Japanese Patients......http://www.natap.org/2011/AASLD/AASLD_68.htm

APSAL1.gif

APSAL2.gif

APSAL3.gif

APSAL4.gif

APSAL5.gif

APSAL6.gif

APSAL7.gif

APSAL8.gif